



Murdin Biotechnology Consulting Inc.  
11 Forest Hill Drive, Richmond Hill, ON L4B 3C2, Canada  
Ph. (905) 237 7688 Cell (647) 669 6604

**Bio: Andrew Murdin, Ph.D.**

Before founding Murdin Biotechnology Consulting Inc. in 2010, Andrew Murdin held the position of Senior Director, External R&D with sanofi pasteur, the world's largest vaccine manufacturer. In this role he was based in Toronto, Canada, and was the senior member of sanofi pasteur's North American External R&D team, responsible for identifying and evaluating novel scientific and technological developments by groups external to sanofi pasteur that were potential in-licensing or acquisition opportunities for sanofi pasteur. He was a member of sanofi pasteur's global Senior Leadership Team from 2007 to 2010.

Until August of 2002 Dr. Murdin was Section Head (Pathogenesis Section) within the Microbiology Platform of sanofi pasteur, also based in Toronto, and was Project Leader for the sanofi pasteur Chlamydia vaccine project. He has extensive experience in the fields of chlamydia and poliovirus vaccine research, and has played a leading role in chlamydia vaccine development at sanofi pasteur.

In response to a corporate need to improve the skills of scientists interacting with business partners and research collaborators, Dr. Murdin led the development and delivery of sanofi pasteur's training program on "Good Partnering Practices". This program provides an overview of business development, legal, patent and alliance management practices for sanofi pasteur's R&D scientists involved in partnerships and collaborations.

Prior to joining sanofi pasteur-Canada in 1990, Andrew was a post-doctoral researcher at the State University of New York, Stony Brook, NY, (1988-1990) and at the University of Surrey, Guildford, UK (1985-1987). While at the State University of New York he helped develop poliovirus vectors as potential immunization vehicles, and while at the University of Surrey he worked on development of large-scale tissue culture systems for the production of biologicals. He holds a Ph.D. from the Department of Microbiology at the University of Surrey, awarded for work on the development of synthetic peptide vaccines for foot-and-mouth disease conducted at the Animal Virus Research Institute, Pirbright, Surrey, UK between 1981 and 1985. Andrew's B.Sc in Applied Biology was awarded by the University of Bath, UK in 1980.

Dr. Murdin is a well-respected professional in the vaccine and biotechnology community. He has authored over 30 refereed papers and book chapters in the area of vaccine development, in addition to abstracts and conference presentations. He is an inventor on 40 granted US patents and 50 pending US patent applications, plus multiple corresponding international patents and patent applications. This includes many patents in the area of chlamydia vaccine antigens, awarded as a result of developing an effective strategy for exploiting chlamydia genome sequence data. He has been a guest lecturer at the University of Toronto on vaccines and vaccination practices, and has given seminars to various technology transfer organizations on the business partnering practices of large pharmaceutical companies.